1.Hypercalciuria associated with nephropathy(diagnosis by renal biopsy).
Hyun Ho SHIN ; Jae Yoon KIM ; Chong Woo BAE ; Sung Ho CHA ; Byoung Soo CHO ; Chang Il AHN ; Young Tae KO ; Moon Ho YANG
Journal of the Korean Pediatric Society 1992;35(11):1509-1513
No abstract available.
Hypercalciuria*
2.Osteocalcin Response to Calcium Restricted Diet for the Selective Therapy of Hypercalciuria.
Young Tae MOON ; Seung Hwan YOON
Korean Journal of Urology 2000;41(4):516-520
No abstract available.
Calcium*
;
Diet*
;
Hypercalciuria*
;
Osteocalcin*
3.Nephrocalcinosis and Hypercalciuria in Children.
Korean Journal of Nephrology 2010;29(3):419-422
No abstract available.
Child
;
Humans
;
Hypercalciuria
;
Nephrocalcinosis
4.Two Cases of Idiopathic Hypercalciuria in Children.
Joon CHO ; Hye Lyung BAIK ; Hong Jong JOO ; Moon Soo PARK ; Jin Keun CHANG ; Sung Woo SHIN
Journal of the Korean Pediatric Society 1988;31(5):635-640
No abstract available.
Child*
;
Humans
;
Hypercalciuria*
5.Hypercalciuria in children : presentation and pathogenesis.
Korean Journal of Nephrology 1993;12(4):626-632
No abstract available.
Child*
;
Humans
;
Hypercalciuria*
6.Idiopathic Hypercalciuria in Children.
Kyung Ha RYU ; Seung Joo LEE ; Keun LEE ; Jae Sun JUNG
Journal of the Korean Pediatric Society 1989;32(6):809-815
No abstract available.
Child*
;
Humans
;
Hypercalciuria*
7.Idiopathic hypercalciuria in children with hematuria.
Ki Young KOO ; Jong Ho LEE ; Cheol Woo KO ; Ja Hoon KOO
Korean Journal of Nephrology 1992;11(3):248-252
No abstract available.
Child*
;
Hematuria*
;
Humans
;
Hypercalciuria*
9.Agglomeration Inhibition (tm) Changes in Absorptive Hypercalciuria Patients after Taking a New Slow-release Potassium Phosphate Preparation (Urophos-K).
Korean Journal of Urology 1995;36(9):939-943
A new slow-release potassium phosphate preparation (Urophos-K), designed to minimize gastrointestinal side effects and avoid sodium-induced calciuria was tested in stone-formers with absorptive hypercalciuria(AH). In a prospective, randomized, double-blind tria1, 17 patients with AH received either Urophos-K (155mg P, 8 mEq K per tablet) 4 tablets twice daily or an identical placebo. Subjects were studied during a 4-day period in the hospital while consuming a constant metabolic diet containing 400mg Ca, 100meq Na, 800mg P/day before and after 3 months of treatment. The parameter of agglomeration inhibition ([h]) increased from 78.3+/-28.1 to 133.3+/-46.2 min4, consistent with the inhibitory action of citrate and pyrophosphate. Treatment with Urophos- K reduces urinary stone-forming potential.
Citric Acid
;
Diet
;
Humans
;
Hypercalciuria*
;
Potassium*
;
Prospective Studies
;
Tablets
10.Circadian Rhythm of ADH, Hypercalciuria, and Solute Diuresis as Pathogenesis of Enuresis.
Journal of the Korean Society of Pediatric Nephrology 2012;16(1):1-8
Nocturnal polyuria is one of the main pathogenic mechanisms of enuresis. Disturbance of circadian rhythm of antidiuretic hormone (ADH or AVP), hypercalciuria, and/or solute diuresis are considered to cause nocturnal polyuria, which in turn causes enuresis in patients with relatively small bladder capacity and high threshold for awakening. Evaluation of these factors would guide the therapeutic approach for enuresis.
Circadian Rhythm
;
Diuresis
;
Enuresis
;
Humans
;
Hypercalciuria
;
Polyuria
;
Urinary Bladder
Result Analysis
Print
Save
E-mail